Abstract
Background:
Increasing use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) raises concern for interactions with warfarin. Although GLP-1 RAs do not affect warfarin pharmacokinetics, their appetite-reducing effects may decrease vitamin K intake and increase International Normalized Ratio (INR) variability. Large-scale real-world data (RWD) are needed to evaluate these effects.
Objectives:
To evaluate changes in time-in-therapeutic INR range (TTR) among warfarin patients initiated on GLP-1 RA therapy.
Methods:
This retrospective cohort study evaluated TTR 6 months before and after GLP-1 RA initiation using RWD from the TriNetX Research Network. Included patients were required to have evidence of warfarin use before and after GLP-1 RA initiation. Primary outcomes included changes in TTR, INR, and INR recheck frequency. Secondary outcomes included time below and above the therapeutic range and INR variability.
Results:
Of 53,943 patients screened, 1,021 met inclusion criteria. Mean TTR decreased by 2.1% (95% CI, −3.7% to −0.6%; p = 0.01), decreasing from 64.2% to 62.1%. Mean INR did not change (0.00; 95% CI, −0.02 to 0.03; p = 0.79). INR recheck frequency increased slightly, with a mean interval decrease of 0.7 days (95% CI −1.4 to 0.0; p = 0.049). Time below therapeutic range increased by 0.8% (p = 0.25), time above therapeutic range increased by 1.3% (p = 0.04), and INR standard deviation increased by 0.03 (p = 0.051).
Conclusions:
GLP-1 RA initiation was associated with a modest decrease in TTR and increased INR variability among warfarin-treated patients. Clinicians may consider closer INR monitoring following GLP-1 RA initiation.
Keywords: Anticoagulation, Warfarin, Glucagon-like Peptide-1 Receptor Agonists, Retrospective Cohort, International Normalized Ratio, Time in Therapeutic Range
Graphical Abstract

The increasing use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) raises concern about potential interactions with narrow therapeutic index medications such as warfarin. This retrospective cohort study evaluated changes in time in therapeutic range (TTR) among patients receiving warfarin during the 6 months before and after GLP-1 RA initiation, using real-world data from the TriNetX Research Network. Among 1,021 patients, mean TTR decreased by 2.1% after GLP-1 RA initiation, while mean international normalized ratio (INR) remained unchanged. Given the potential for increased INR variability, clinicians may consider increasing INR monitoring frequency following GLP-1 RA initiation.
Introduction
The widespread adoption of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) over the past decade has raised concerns about potential interactions with other medications. The main actions of GLP-1 RAs include increasing glucose-dependent insulin secretion from the pancreas, decreasing inappropriate glucagon secretion, slowing gastric emptying, and helping regulate appetite and caloric intake by stimulating the hypothalamus [1, 2]. These mechanisms lead many to lose weight [3–7]. While initially approved for the treatment of type 2 diabetes, the FDA has now approved several GLP-1 RAs for weight loss [8–10]. Consequently, GLP-1 RA prescriptions in the US have significantly increased in recent years [11]. With increasing GLP-1 RAs use, it is important to consider how altering appetite, caloric intake, and gastric emptying may affect drug absorption and nutrient intake. Medications like warfarin with a narrow therapeutic index and known diet-drug interactions are most likely to be affected by the altered nutrient intake associated with GLP-1 RAs [12].
Warfarin is a commonly prescribed vitamin K antagonist anticoagulant [12]. Since vitamin K is found in many foods, variations in dietary intake can affect warfarin’s anticoagulant effect. This is among the reasons why patients prescribed warfarin require international normalized ratio (INR) monitoring to ensure therapeutic anticoagulation levels [13]. Maximizing time in the therapeutic INR range (TTR) is crucial for patients on warfarin, as subtherapeutic levels put patients at higher risk of thromboembolic events and supratherapeutic levels carry a higher risk of bleeding [14].
Several studies have found no significant effect of concomitant GLP-1 RAs use on warfarin pharmacokinetics [15–18]. However, GLP-1 RA use predictably results in decreased appetite and caloric intake [1, 2]. This in turn may alter dietary vitamin K consumption and destabilize INR response, but this has not been studied in large populations using real-world data (RWD). The possibility remains that a pharmacodynamic interaction between warfarin and GLP-1 RAs exists and could be observed using RWD from large patient cohorts. A large study population is crucial, as individual vitamin K consumption varies widely. Initiating a GLP-1 RA may cause significant INR fluctuations in some individuals, but minimal to no change in others. Using a large RWD study population could allow for subtle but clinically important trends and patterns to emerge.
Understanding how GLP-1 RA initiation affects warfarin therapy is important because starting or stopping interacting medications typically prompt clinicians to check INRs more frequently [19]. Increasing INR recheck frequency facilitates warfarin dose adjustments and helps maintain optimal TTR. In the US healthcare system — where patients often receive prescriptions from multiple clinicians across different practices or health systems — recognizing how GLP-1 RA initiation could influence INR control would allow clinicians managing warfarin to adjust INR monitoring accordingly.
This study examined changes in TTR, INR values, and INR recheck frequency following GLP-1 RA initiation in a large real-world dataset to evaluate a potential indirect interaction between GLP-1 RAs and warfarin.
Methods
Study Design and Setting
This was a retrospective, longitudinal, pre-post cohort study that included data from the TriNetX Research Collaborative Network through November 12, 2024 [20]. For each eligible patient, the date of GLP-1 RA initiation served as the index date. Outcomes were assessed during the 180 days before and after the index date. The study was reviewed and approved by the University of Utah Institutional Review Board and determined to be exempt.
Study Cohort
The following criteria were used to include patients receiving ongoing warfarin with regular INR monitoring who initiated a GLP-1 RA in the analysis: 1) a warfarin prescription within the year prior to GLP-1 RA initiation—if the prescription occurred within 90 days of initiation, a second warfarin prescription within the preceding year was required; 2) a warfarin prescription within 13 months following GLP-1 RA initiation; 3) a second GLP-1 RA prescription within 90 days of the initial GLP-1 RA prescription; 4) INR measurements in the 6 months before and after GLP-1 RA initiation (to support TTR interpolation, at least one INR value had to occur more than 180 days before initiation and another more than 180 days after); and 5) no INR recheck interval longer than 12 weeks.
TriNetX is a federated network that provides access to de-identified electronic medical record data from multiple healthcare organizations, including hospitals, primary care, and specialty care providers across diverse geographical regions and patient populations [20]. Data obtained from TriNetX included information on patient demographics, medications, laboratory results, diagnoses, and vital signs extracted from electronic health records. Demographic information included sex, race, ethnicity, and year of birth. Medication data included medication code (RxNorm) and start date. Laboratory results included lab code (LOINC), date, value, and units. Diagnoses included diagnosis code (ICD-9 and ICD-10) and date. Vital signs included BMI (LOINC), date, and value.
Study Outcomes
The primary study outcomes were changes in TTR, INR values, and INR recheck frequency before and after GLP-1 RA initiation. Secondary outcomes included changes in time below and above the therapeutic INR range before and after GLP-1 RA initiation, as well as changes in within-patient INR standard deviation to assess variability.
Data Analysis
Mean values and 95% confidence intervals were calculated for TTR, INR recheck frequency, and time below and above therapeutic INR range. Mean paired differences and 95% confidence intervals were calculated for within-patient INR summary measures. Proportions were used to summarize categorical variables. Missing data for age, sex, race, ethnicity, and BMI were handled using complete-case analysis for each variable. Paired t-tests were used to evaluate changes in primary and secondary outcomes, with two-sided p-values <0.05 considered statistically significant. Statistical analyses were performed using Python (version 3.12.7) with the pandas, NumPy, and SciPy libraries.
TTR was calculated using linear interpolation [21]. For each patient, INR values were estimated on the date of GLP-1 RA initiation and at 180 days before and after initiation. When no INR measurements existed on these dates, the values were interpolated from the nearest preceding and following INR results. These observed or estimated INR values served as the anchor points for calculating TTR in the 6-months periods before and after GLP-1 RA initiation. As individual INR goal range data was unavailable, each patient was assumed to have an INR target range of 2.0 – 3.0 for TTR calculation.
Changes in INR were assessed using patient-level summary measures. For each patient, the median INR value was calculated separately for the pre- and post-index periods. These patient-specific median INR values were then averaged across the study population to obtain a mean INR for each period. Trends in INR values over time were evaluated using locally estimated scatterplot smoothing (LOESS) applied to all available INR measurements relative to the index date [22]. Within-patient INR standard deviation was also calculated for the pre- and post-index periods. Outcomes were evaluated in the overall study population and across prespecified subgroups to explore potential differences by sex, race, ethnicity, age, BMI, and comorbid conditions (heart failure, hypertension, history of stroke, vascular disease, diabetes, liver disease, and kidney disease).
Results
Of the 53,943 patients in the TriNetX Research Network with prescriptions for warfarin and GLP-1 RAs, 1,021 were included in the study (Figure 1). Included patients were primarily middle-aged to elderly (mean age 62.3 years), male (54.9%), and of White race (78.8%) and non-Hispanic ethnicity (94.4%) (Table 1). Diabetes and hypertension were common comorbid diseases (82.6% and 80.5%, respectively).
Figure 1.

Inclusion Criteria Flowchart
GLP-1 RA, glucagon-like peptide-1 receptor agonist; INR, international normalized ratio.
Table 1.
Patient Characteristics (n=1,021)
| Characteristic | Value |
|---|---|
| Mean age* in years (SD) | 62.3 (12.2) |
| Sex, n (%) | |
| Female | 440 (45.1) |
| Male | 535 (54.9) |
| Race, n (%) | |
| American Indian or Alaska Native | 4 (0.4) |
| Asian | 19 (2.1) |
| Black or African American | 142 (15.6) |
| Native Hawaiian or Other Pacific Islander | 9 (1.0) |
| White | 719 (78.8) |
| Other Race | 19 (2.1) |
| Ethnicity, n (%) | |
| Hispanic or Latino | 48 (5.6) |
| Not Hispanic or Latino | 816 (94.4) |
| Mean BMI† (SD) | 37.8 (7.0) |
| Comorbidities‡, n (%) | |
| Heart failure | 405 (39.7) |
| Hypertension | 822 (80.5) |
| Stroke/TIA/arterial systemic embolism | 125 (12.2) |
| Vascular disease | 212 (20.8) |
| Diabetes | 843 (82.6) |
| Liver disease | 84 (8.2) |
| Kidney disease | 388 (38.0) |
| Missing values, n | |
| Age | 15 |
| Sex | 46 |
| Race | 109 |
| Ethnicity | 157 |
| BMI | 339 |
SD, standard deviation; TIA, transient ischemic attack
As of the year of GLP-1 RA initiation.
Most recent BMI recorded in patient records 180 days prior to the GLP-1 RA initiation date.
Diagnosis recorded in patient records 180 days prior to the GLP-1 RA initiation date.
Following GLP-1 RA initiation, TTR decreased by 2.1% (95% CI, −3.7 to −0.6; p = 0.01), the mean INR value remained unchanged (95% CI, −0.02 to 0.03; p = 0.79), and the mean INR recheck interval decreased by 0.7 days (95% CI, −1.4 to 0.0; p = 0.049) (Table 2). Time below the therapeutic range increased by 0.8% (95% CI, −0.5 to 2.1; p = 0.25), and time above the therapeutic range increased by 1.3% (95% CI, 0.1 to 2.6; p = 0.04). See Online Resource 1 for a graphical representation of the change in TTR, time below therapeutic range, and time above therapeutic range. In analysis of INR variability, the within-patient INR standard deviation increased from 0.63 in the pre-index period to 0.66 in the post-index period (95% CI, 0.00 to 0.05; p = 0.051).
Table 2.
Primary and Secondary Outcomes Pre- and Post-Index Date
| Outcome | Pre-Index | Post-index | Mean Change [95% CI] | P-value |
|---|---|---|---|---|
| Primary Outcomes | ||||
| TTR, % | 64.2 | 62.1 | −2.1 [−3.7 to −0.6] | 0.01 |
| INR values | 2.38 | 2.39 | 0.00 [−0.02 to 0.03] | 0.79 |
| INR recheck interval, days | 19.6 | 18.9 | −0.7 [−1.4 to 0.0] | 0.049 |
| Secondary Outcomes | ||||
| Time below therapeutic range, % | 19.7 | 20.5 | 0.8 [−0.5 to 2.1] | 0.25 |
| Time above therapeutic range, % | 16.1 | 17.5 | 1.3 [0.1 to 2.6] | 0.04 |
| INR variability (SD) | 0.63 | 0.66 | 0.03 [0.00 to 0.05] | 0.051 |
TTR, time in therapeutic range; INR, international normalized ratio.
The distribution of patient TTRs before and after GLP-1 RA initiation is summarized in Figure 2 and the LOESS plot of mean INR values over the study period and corresponding 95% confidence interval in Figure 3.
Figure 2.

TTR distribution comparison: before to after GLP-1 RA initiation
Figure 3.

Mean INR Trend Over Time Pre- and Post-Index Date (LOESS, 95% CI)
Figure 2 illustrates a shift in the distribution of patient TTR categories from before to after GLP-1 RA initiation, with a decrease in the proportion of patients with TTRs of 80 to 95% and little change in those with TTRs of 95 to 100%. A greater proportion of patients fell within the 30 to 60% TTR range after GLP-1 RA initiation.
Figure 3 demonstrates minimal variation in the population mean INR over the study period, with the LOESS trend and corresponding 95% confidence interval remaining largely stable before and after GLP-1 RA initiation.
In subgroup analyses, patients aged 75 and older were the only age group with a statistically significant mean TTR decrease of −4.8% (95% CI, −8.9 to −0.8; p = 0.02) (see Online Resource 2). The mean TTR decrease in males was −3.1% (95% CI, −5.3 to −0.9; p = 0.01), whereas in females it was −0.3% (95% CI, −2.5 to 1.9; p = 0.78). Among racial groups, the mean TTR decrease in White patients was −2.3% (95% CI, −4.1 to −0.4; p = 0.02). Non-Hispanic or Latino patients showed a mean decrease in TTR of −2.3% (95% CI, −4.0 to −0.6; p = 0.01;).
Discussion
Overall, the effect of GLP-1 RA initiation on INR control among patients using ongoing warfarin therapy was modest. The 2.1% decrease in TTR was accompanied by increases in both time below and time above the therapeutic range (0.8% and 1.3%, respectively), as well as a modest rise in within-patient INR variability (SD +0.03), while mean INR values remained unchanged before and after GLP-1 RA initiation. This pattern suggests that GLP-1 RA initiation may be associated with increased INR variability rather than a unidirectional shift in anticoagulation intensity. The slight decrease in the INR recheck interval may reflect clinicians responding to this increased variability by monitoring INRs more frequently.
In subgroup analyses provided in Online Resource 2, statistically significant decreases in TTR following GLP-1 RA initiation were observed among patients aged 75 years and older and male patients (−4.8% and −3.1%, respectively). These groups also had high pre-GLP-1 RA TTR values (69.1% and 66.5%, respectively). One possible explanation for larger TTR declines in these subgroups is the ceiling effect: patients who begin with better baseline INR control have more potential for TTR to decrease and less capacity for further improvement. White and non-Hispanic or Latino patients also experienced statistically significant decreases in TTR; however, this may partly reflect the greater statistical power to detect differences in these groups, which comprised most of the study population (78.8% and 94.4%, respectively).
Figure 2 shows that the largest reduction in patient counts after GLP-1 RA initiation occurred among individuals with baseline TTR between 80 to 95%. In contrast, patients with near-perfect INR control (TTR 95 to 100%) showed little change after GLP-1 RA initiation. This stability likely reflects underlying characteristics such as high medication adherence, frequent INR monitoring, and stable dietary vitamin K intake. These protective behaviors may buffer this subgroup from the INR destabilization that can accompany GLP-1 RA-related physiological changes. Overall, the observed redistribution of TTR categories suggests that GLP-1 RA initiation may disproportionately influence patients with moderately high—but not optimal—baseline INR stability. Although the observational design precludes firm causal conclusions, the temporal relationship and biological plausibility indicate that enhanced INR monitoring may be particularly important for this subgroup during early GLP-1 RA therapy.
While these findings provide valuable insight into a potential interaction between GLP-1 RAs and warfarin, the duration of this interaction remains challenging to determine. As shown in Figure 3, the LOESS-smoothed mean INR values remain relatively stable throughout the 6-month period following GLP-1 RA initiation, with no obvious inflection point or sustained deviation from baseline. This stability limits the utility of mean INR trends for identifying when any interaction might begin or resolve. Conversely, although TTR is more sensitive to cumulative INR variability, it requires multiple INR measurements over time and therefore cannot precisely localize the onset or offset of changes in anticoagulation control. As a result, our data cannot distinguish whether any GLP-1 RA—warfarin interaction persists for less than, more than, or approximately 6 months after initiation. The true duration may depend on how quickly patients stabilize both their GLP-1 RA dosing and their associated lifestyle changes—such as weight loss trajectory and dietary patterns—following initiation.
Strengths of this study include the use of a large, multi-center real-world dataset, which allows for the evaluation of population-level trends and enhances the generalizability of the findings. Additionally, rigorous cohort definitions were applied to identify patients with ongoing warfarin therapy at the time of GLP-1 RA initiation and to ensure continued warfarin and GLP-1 RA therapy throughout the study period. Finally, the pre-post longitudinal study design allowed each patient to serve as their own control, thereby reducing confounding from time-invariant individual characteristics.
This study has several important limitations. First, the inclusion criteria required ongoing warfarin therapy and sufficient INR measurements in both the 6-month pre- and post-GLP-1 RA initiation periods to support reliable TTR estimation. While necessary for valid interpolation, this design preferentially selected patients with sustained healthcare engagement and introduced potential selection and immortal time bias. Specifically, patients were required to remain alive and under observation long enough to contribute INR data, which may underrepresent individuals who experienced early complications, severe bleeding events, treatment discontinuation, or death after GLP-1 RA initiation. As a result, our findings may underestimate the magnitude of INR instability in higher-risk patients who could not be captured due to limited follow-up.
Second, comorbidities were assessed at baseline, and changes in comorbidity burden, intercurrent illness, hospitalizations, or bleeding events during follow-up could not be comprehensively characterized. Although INR monitoring may continue during hospitalizations or acute illness, the TriNetX dataset has limited ability to capture event severity, out-of-network encounters, and cause-specific mortality, which may influence anticoagulation control.
Third, several individual-level factors known to influence INR control were not available in this dataset. Dietary vitamin K intake is a key determinant of warfarin response and may contribute to INR variability. Changes in appetite and dietary patterns following GLP-1 RA initiation could therefore influence INR stability, particularly among patients with higher baseline vitamin K intake. Other relevant factors, such as medication adherence, warfarin dose changes, and GLP-1 RA dosing, were also unavailable and could not be assessed.
Fourth, because individual INR target ranges were not available, an INR target range of 2.0 – 3.0 was assumed for all patients. As some patients may have had alternative INR target ranges, overall TTR values may be underestimated. However, this assumption was applied consistently to both the pre-index and post-index periods and is therefore unlikely to affect within-patient comparisons of change over time. Finally, due to the retrospective observational design, residual confounding from unmeasured variables remains possible.
Conclusion
A modest decrease in TTR and small increase in INR variability were observed in this study, while the net INR value remained unchanged throughout the study period. Although the absolute reduction in TTR was small, even modest increases in INR variability may be clinically relevant for individual patients, particularly early after therapy changes. These findings support increased awareness and more frequent INR monitoring for warfarin patients after GLP-1 RA initiation rather than changes in dosing strategies. Further analysis into factors that could contribute to individuals being at higher risk of INR variability after GLP-1 RA initiation is needed.
Supplementary Material
Key Points.
Among 1,021 patients receiving warfarin, TTR decreased by 2.1% following GLP-1 RA initiation
Time above the therapeutic INR range increased significantly after GLP-1 RA initiation, while time below range showed a numerical increase
Mean INR values did not significantly change following GLP-1 RA initiation, but within-patient INR variability increased slightly.
Clinicians may consider closer INR monitoring due to potential increased INR variability after GLP-1 RA initiation
Acknowledgements
The data used in this study was collected on 11/12/2024 from the TriNetX Research Network, which provided access to electronic medical records (diagnosis, procedures, medications, laboratory values, genomic information) from approximately 130 million patients from 120 healthcare organizations. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Department of Defense, the National Institutes of Health, or the National Library of Medicine.
Funding
This work was supported by the National Library of Medicine (5T15LM007124-24 to SJG); the Utah Clinical and Translational Science Institute (CTSA award UM1TR004409 to JCF and RG); and the Department of Defense (DoD) SMART Scholarship-for-Service Program (AM).
Footnotes
Statements and Declarations
SRV – Advisory Council for the Anticoagulation Forum, editorial consultant for UptoDate warfarin topics; DMW – Advisory Council for the Anticoagulation Forum; SJG, RG, AM, JCF – no conflicts to disclose
References
- [1].Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab. 2018;27(4):740–56. [DOI] [PubMed] [Google Scholar]
- [2].Smith NK, Hackett TA, Galli A, Flynn CR. GLP-1: Molecular mechanisms and outcomes of a complex signaling system. Neurochem Int. 2019;128:94–105. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [3].Davies M, Faerch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971–84. [DOI] [PubMed] [Google Scholar]
- [4].Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, Aizenberg D, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023;402(10402):613–26. [DOI] [PubMed] [Google Scholar]
- [5].Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205–16. [DOI] [PubMed] [Google Scholar]
- [6].Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373(1):11–22. [DOI] [PubMed] [Google Scholar]
- [7].Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989–1002. [DOI] [PubMed] [Google Scholar]
- [8].Novo Nordisk. Wegovy (semaglutide) [package insert]. US Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215256s007lbl.pdf. Revised July 2023. Accessed October 2024. [Google Scholar]
- [9].Novo Nordisk. Saxenda (liraglutide) [package insert]. US Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206321Orig1s000lbl.pdf. Revised December 2014. Accessed October 2024. [Google Scholar]
- [10].Eli Lilly and Company. Zepbound (tirzepatide) [package insert]. US Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217806s000lbl.pdf. Revised November 2023. Accessed October 2024. [Google Scholar]
- [11].Ukhanova M, Wozny JS, Truong CN, Ghosh L, Krause TM. Trends in glucagon-like peptide 1 receptor agonist prescribing patterns. Am J Manag Care. 2025;31(8):e228–e34. [DOI] [PubMed] [Google Scholar]
- [12].Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e44S–e88S. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [13].Witt DM, Clark NP, Kaatz S, Schnurr T, Ansell JE. Guidance for the practical management of warfarin therapy in the treatment of venous thromboembolism. J Thromb Thrombolysis. 2016;41(1):187–205. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [14].Shikdar S, Vashisht R, Zubair M, Bhattacharya PT. International Normalized Ratio: Assessment, Monitoring, and Clinical Implications. StatPearls. Treasure Island (FL)2025. [PubMed] [Google Scholar]
- [15].Baekdal TA, Borregaard J, Hansen CW, Thomsen M, Anderson TW. Effect of Oral Semaglutide on the Pharmacokinetics of Lisinopril, Warfarin, Digoxin, and Metformin in Healthy Subjects. Clin Pharmacokinet. 2019;58(9):1193–203. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [16].Bogman K, Brumm J, Hofmann C, Giraudon M, Niggli M, Sturm-Pellanda C, et al. Assessment of Drug-Drug Interactions between Taspoglutide, a Glucagon-Like Peptide-1 Agonist, and Drugs Commonly Used in Type 2 Diabetes Mellitus: Results of Five Phase I Trials. Clin Pharmacokinet. 2019;58(9):1205–14. [DOI] [PubMed] [Google Scholar]
- [17].Calvarysky B, Dotan I, Shepshelovich D, Leader A, Cohen TD. Drug-Drug Interactions Between Glucagon-Like Peptide 1 Receptor Agonists and Oral Medications: A Systematic Review. Drug Saf. 2024;47(5):439–51. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [18].Hausner H, Derving Karsbol J, Holst AG, Jacobsen JB, Wagner FD, Golor G, et al. Effect of Semaglutide on the Pharmacokinetics of Metformin, Warfarin, Atorvastatin and Digoxin in Healthy Subjects. Clin Pharmacokinet. 2017;56(11):1391–401. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [19].Vazquez SR. Drug-drug interactions in an era of multiple anticoagulants: a focus on clinically relevant drug interactions. Blood. 2018;132(21):2230–9. [DOI] [PubMed] [Google Scholar]
- [20].TriNetX L. TriNetX Research Collaborative Network 2024. [Available from: https://trinetx.com.
- [21].Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993;69(3):236–9. [PubMed] [Google Scholar]
- [22].Cleveland WS, Devlin SJ. Locally Weighted Regression - an Approach to Regression-Analysis by Local Fitting. J Am Stat Assoc. 1988;83(403):596–610. [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
